Search Results

You are looking at 11 - 20 of 1,114 items for :

  • "breast cancer" x
  • Refine by Access: All x
Clear All
Full access

Therese B. Bevers, Mark Helvie, Ermelinda Bonaccio, Kristine E. Calhoun, Mary B. Daly, William B. Farrar, Judy E. Garber, Richard Gray, Caprice C. Greenberg, Rachel Greenup, Nora M. Hansen, Randall E. Harris, Alexandra S. Heerdt, Teresa Helsten, Linda Hodgkiss, Tamarya L. Hoyt, John G. Huff, Lisa Jacobs, Constance Dobbins Lehman, Barbara Monsees, Bethany L. Niell, Catherine C. Parker, Mark Pearlman, Liane Philpotts, Laura B. Shepardson, Mary Lou Smith, Matthew Stein, Lusine Tumyan, Cheryl Williams, Mary Anne Bergman, and Rashmi Kumar

average lifetime risk of breast cancer for a woman in the United States has been estimated at 12.3% (ie, 1 in 8 women). 1 For 2018, the American Cancer Society (ACS) estimates that 63,960 cases of female carcinoma in situ of the breast and 268,670 cases

Full access

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead, and Rashmi Kumar

American Cancer Society estimates that 249,260 Americans will be diagnosed with invasive breast cancer and 40,890 will die of the disease in the United States in 2016. 1 Breast cancer is the most frequently diagnosed cancer globally and the leading cause

Full access

Robert W. Carlson and on behalf of the NCCN Breast Cancer Panel

The past 10 years have witnessed multiple important advances in the systemic treatment of breast cancer ( Table 1 ). These advances have resulted from a better understanding of the underlying biology of breast cancer, the development of new

Full access

Arvind Bambhroliya, Mariana Chavez-MacGregor, and Abenaa M. Brewster

cancer risk reduction medications Explain several strategies to educate women on breast cancer risk and risk reduction strategies Identify research areas to improve the use of risk reduction medication for women who are at high risk for breast cancer

Full access

Robert W. Carlson, Susan Moench, Arti Hurria, Lodovico Balducci, Harold J. Burstein, Lori J. Goldstein, William J. Gradishar, Kevin S. Hughes, Mohammad Jahanzeb, Stuart M. Lichtman, Lawrence B. Marks, Joan S. McClure, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Mary Lou Smith, Neal S. Topham, Tiffany A. Traina, John H. Ward, and Eric P. Winer

Overview and Rationale A lthough breast cancer is common in older women, guidance on optimal treatment is limited by their low enrollment in randomized clinical trials. The Surveillance Epidemiology and End Results (SEER) database shows that the

Full access

Puyao C. Li, Zilu Zhang, Angel M. Cronin, and Rinaa S. Punglia

Background Women with a history of ductal carcinoma in situ (DCIS) are at increased risk for developing a second breast cancer (SBC) in either the ipsilateral or contralateral breast. 1 , 2 Many women receive breast-conserving surgery (BCS) with

Full access

Therese B. Bevers, Benjamin O. Anderson, Ermelinda Bonaccio, Sandra Buys, Mary B. Daly, Peter J. Dempsey, William B. Farrar, Irving Fleming, Judy E. Garber, Randall E. Harris, Alexandra S. Heerdt, Mark Helvie, John G. Huff, Nazanin Khakpour, Seema A. Khan, Helen Krontiras, Gary Lyman, Elizabeth Rafferty, Sara Shaw, Mary Lou Smith, Theodore N. Tsangaris, Cheryl Williams, and Thomas Yankeelov

Breast Cancer Screening and Diagnosis Clinical Practice Guidelines in Oncology NCCN Categories of Evidence and Consensus Category 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is

Full access

Omalkhair Abulkhair, Nagi Saghir, Lobna Sedky, Ahmed Saadedin, Heba Elzahwary, Neelam Siddiqui, Mervat Al Saleh, Fady Geara, Nuha Birido, Nadia Al-Eissa, Sana Al Sukhun, Huda Abdulkareem, Menar Mohamed Ayoub, Fawaz Deirawan, Salah Fayaz, Alaa Kandil, Sami Khatib, Mufid El-Mistiri, Dorria Salem, El Siah Hassan Sayd, Mohammed Jaloudi, Mohammad Jahanzeb, and William I. Gradishar

dramatically in developed countries, including the United States, Canada, Australia, and Europe. This reduction could be attributed to the efficacy of mammography in detecting early-stage breast cancer, 4 , 5 and to the introduction of adjuvant systemic

Full access

Zeynep Eroglu, Odicie Fielder, and George Somlo

Through coordinated scientific, medical, and public health advances, 5-year survival rates for breast cancer approach 90%. However, microscopic residual disease frequently results in local relapse or metastasis, leading to approximately 40

Full access

Rita A. Mukhtar, Jasmine M. Wong, and Laura J. Esserman

economically and potentially as direct toxicity to the patient. Mukhtar and colleagues provide a thought-provoking discussion of these issues as they apply to breast cancer care. The overdiagnosis of breast cancers that may have remained indolent and have